Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).
Merck (NYSE: MRK) has recently announced the completion of the acquisition of Eyebiotech Limited (EyeBio), now becoming a wholly-owned subsidiary of Merck. EyeBio was founded… Read More »Merck (NYSE: MRK) and Eyebiotech Ltd (UK) completes acquisition, following a recent experimental treatment (“Restoret”) for diabetic macular edema (DME).